XML 26 R11.htm IDEA: XBRL DOCUMENT
v3.24.1

COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION | 12 Months Ended
--- | ---
Dec. 31, 2023
Equity [Abstract] |
COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION | NOTE 5 – COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION
| A. | Description of the rights attached to the Common Stock
|  | Each share of Common Stock entitles the holder to one vote, either in person or by proxy, on each matter submitted to the approval of the Company’s stockholders. The holders of Common Stock are not permitted to vote their shares cumulatively.
| B. | Completion of underwritten U.S. public offering
|  | On April 13, 2023, the Company completed an underwritten public offering under which the Company received gross proceeds of approximately $10 million for issuance of (i) 5,376,472 shares of common stock and (ii) 1,976,470 pre-funded warrants at a price to the public of $1.36 per share. The pre-funded warrants are exercisable for the same number of shares of common stock and may be exercised at any time until exercised in full at an exercise price of $0.001. Upon satisfaction of customary closing conditions, the closing date of the above underwritten public offering was April 17, 2023 (the “Closing Date”). The Company received substantially all the pre-funded warrant’s proceeds upfront (without any conditions) as part of the pre-funded warrant’s purchase price and in return the Company is obligated to issue fixed number of 1,976,470 shares of Common Stock to the holders. Thus, pre-funded warrants were accounted for and were classified as additional paid-in capital as part of the Company’s stockholders’ equity. Total incremental and direct issuance costs amounted to $1,270 thousand. These expenses were deducted from additional paid-in capital as they were allocated to shares of Common Stock and pre-funded warrants. On January 3, 2024, the above pre-funded warrants have been fully exercised to 1,976,470 shares of Common Stock of the Company.
| C. | Stock-based compensation
| 1. | Plan
|  | On January 11, 2010, the Company’s Board of Directors approved and adopted the 2010 Share Incentive Plan (the “Plan”), pursuant to which the Company’s Board of Directors may award share options to purchase the Company’s Common Stock as well as restricted shares, Restricted Stock Units (the “RSU”) and other share-based awards to designated participants. Subject to the terms and conditions of the Plan, the Company’s Board of Directors has full authority in its discretion, from time to time and at any time, to determine (i) the designate participants; (ii) the terms and provisions of the respective award agreements, including, but not limited to, the number of share options to be granted to each optionee, the number of shares to be covered by each share option, provisions concerning the time and the extent to which the share options may be exercised and the nature and duration of restrictions as to the transferability or restrictions constituting substantial risk of forfeiture and to cancel or suspend awards, as necessary; (iii) determine the fair market value of the shares covered by each award; (iv) make an election as to the type of approved 102 Option under Israeli tax law; (v) designate the type of share options; (vi) take any measures, and to take actions, as deemed necessary or advisable for the administration and implementation of the Plan; (vii) interpret the provisions of the Plan and to amend from time to time the terms of the Plan.
| 2. | Grant of equity awards to employees
| A. | In October 2022, the Company granted Mr. Mark Tapsak, the Vice President, Sensor Science of the Company, 115,857 options estimated at fair value of $22, to purchase the same number of Common Stock, with an exercise price per share equals to the greater of (A) $5.2 per share or (B) the closing price of a share of Common Stock on the grant date, as reported by Bloomberg L.P., which shall vest in equal monthly installments over a period of 3-years following the grant date.
| B. | In August 2023, the Company granted Mrs. Drinda Benjamin, the Vice President, Marketing of the Company, 222,016 options estimated at fair value of $51, to purchase the same number of Common Stock, with an exercise price per share equals to the greater of (A) $1.36 per share or (B) the closing price of a share of Common Stock on the grant date, as reported by Bloomberg L.P., which shall vest in equal monthly installments over a period of 3-years following the grant date.
| C. | During the years ended December 31, 2023 and 2022, the Company recorded stock-based compensation expenses of $281 and $439, respectively.
| D. | The following table presents the Company’s stock options (excluding RSU) activity for employees and members of the Board of Directors of the Company under the Plan, for the years ended December 31, 2023 and 2022:
SCHEDULE OF SHARE OPTION ACTIVITY FOR EMPLOYEES AND MEMBERS
|  | Number of Share Options |  |  | Weighted Average Exercise Price |  |  | Weighted average remaining contractual life |  |  | Intrinsic value |
|  |  |  |  | $ |  |  | (years) |  |  | $ |
Outstanding as of December 31, 2021 |  |  | 620,053 |  |  |  | 8.0 |  |  |  | 3.0 |  |  |  | - |
Granted |  |  | 115,857 |  |  |  | 5.2 |  |  |  | 2.7 |  |  |  | - |
Forfeited or expired |  |  | (26,923 | ) |  |  | 64.5 |  |  |  | 1.7 |  |  |  | - |
Outstanding as of December 31, 2022 |  |  | 735,910 |  |  |  | 7.6 |  |  |  | 2.1 |  |  |  | - |
Exercisable as of December 31, 2022 |  |  | 245,535 |  |  |  | 12.4 |  |  |  | 2.6 |  |  |  | - |
|  | Number of Share Options |  |  | Weighted Average Exercise Price |  |  | Weighted average remaining contractual life |  |  | Intrinsic value |
|  |  |  |  | $ |  |  | (years) |  |  | $ |
Outstanding as of December 31, 2022 |  |  | 735,910 |  |  |  | 7.6 |  |  |  | 2.1 |  |  |  | - |
Granted |  |  | 222,016 |  |  |  | 1.4 |  |  |  | 9.7 |  |  |  | - |
Forfeited or expired |  |  | (26,923 | ) |  |  | 64.5 |  |  |  | 1.7 |  |  |  | - |
Outstanding as of December 31, 2023 |  |  | 931,003 |  |  |  | 4.5 |  |  |  | 8.0 |  |  |  | - |
Exercisable as of December 31, 2023 |  |  | 500,984 |  |  |  | 5.6 |  |  |  | 7.9 |  |  |  | - |
| The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the deemed fair value of the Company’s Ordinary Shares on the last day of each of the applicable reported period and the exercise price, multiplied by the number of in-the-money share options) that would have been received by the share option holders had all share options holders exercised their share options on December 31 of each of the reported period. This amount is impacted by the changes in the fair market value of the Company’s Ordinary Share.
| E. | During the years ended December 31, 2023 and 2022, stock options have not been exercised into Common Stock.
| F. | The following table presents the assumptions used to estimate the fair values of the share options granted in the reported periods presented:
SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS
|  | Years ended December 31 |
|  | 2023 |  |  | 2022 |
Volatility (%) |  |  | 220 | % |  |  | 72.15 | %
Risk-free interest rate (%) |  |  | 4.7 | % |  |  | 2.5 | %
Dividend yield (%) |  |  | - |  |  |  | - |
Expected life (years) |  |  | 3 |  |  |  | 3 |
Exercise price ($) |  |  | 1.4 |  |  |  | 5.2 |
Share price ($) |  |  | 0.3 |  |  |  | 1.9 |
| G. | As of December 31, 2023, there was $83 of unrecognized compensation expense related to unvested stock options. The Company recognizes compensation expense on an accelerated vesting basis over the requisite service periods, which results in a weighted average period of approximately 1.9 years over which the unrecognized compensation expense is expected to be recognized.
| 3. | Grant of equity awards to non-employees
| A. | In connection with 2017 Offering, the Company has issued to Andrew Garrett Inc, who served as a placement agent in fundraising transaction (a) 5-years warrants to purchase up to 4,068,498 shares of Common Stock at an exercise price of $3.35 per share, (b) 5-years warrants to purchase up to 8,331 shares of Common Stock at an exercise price of $23.4 per share, (c) 5-years warrants to purchase up to 8,331 shares of Common Stock at an exercise price of $46.8 per share and (d) 5-years warrants to purchase up to 8,331 shares of Common Stock at an exercise price of $70.2 per share. In connection with February 2020 Offering, the Company has issued to the Andrew Garrett Inc, who served as a placement agent a 5-years warrants to purchase up to 288,462 shares of Common Stock at an exercise price of $5.2 per share.
| B. | On September 12, 2022, the Company signed on Advisory agreement with Andrew Garrett Inc, under which the Company agreed to extend the exercise through July 1, 2026, for all warrants issued pursuant to the Exchange Agreement dated December 31, 2018. The Company accounted for the extension of the warrants exercise period pursuant to ASC 718 as a modification. Accordingly, additional compensation of $56 was calculated as the fair value of the modified award in excess of the fair value of the original award measured immediately before its terms have been modified. The incremental fair value was recognized as an immediate expense in 2022 as the warrants were fully vested at the modification date.
| C. | Upon closing of underwritten U.S. public offering as noted in Note 5B above, a down round protection feature of all the above warrants, was triggered through the reduction of their original exercise prices from a price in a range of $3.35-$70.2 to a price of $1.36 which represented the public offering price. Such reduction was accounted for in accordance with the provisions of ASU 2017-11as a deemed dividend estimated at a total amount of $855 thousand which was recorded as part of the additional paid-in capital versus increase of accumulated deficit. Regarding the effect of the loss per share, see also Note 2K above.
| D. | For more information regarding the exchange of the above warrants to share of the Company’s Common Stock, see also Note 10A below.
| The total compensation cost related to all of the Company’s equity-based awards recognized during the years ended December 31, 2023 and 2022 was comprised as follows:
SCHEDULE OF TOTAL COMPENSATION COST EQUITY BASED AWARDS
Research and Development |  | December 31, 2023 |  |  | December 31, 2022 |
|  | In thousands of US dollars |
|  | December 31, 2023 |  |  | December 31, 2022 |
Research and development |  |  | 176 |  |  |  | 92 |
General and administrative |  |  | 159 |  |  |  | 395 |
Total compensation cost |  |  | 335 |  |  |  | 487 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration